Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Hims & Hers (NYSE:HIMS) has launched an online GLP-1 supply tracker where people can share information about where the ...

Subscriber growth surged 44% y/y to 2.05 million. It's also worth noting that ex-GLP 1 subgrowth would have been 40% y/y, ...

Meanwhile, the company said that 85% of GLP-1 subscribers continue to take their prescriptions four weeks after it is first ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...